<p><em>拟议对总部位于德国的 PAD Aviation 进行战略投资，这是一家顶级的欧洲私人航空运营商，旨在为 TransMedics 在欧洲建立专门的器官移植空中物流网络奠定基础</em></p>
<p>, /PRNewswire/ -- TransMedics Group, Inc.（&#34;TransMedics&#34;）（纳斯达克：TMDX），一家正在改变终末期肺、心脏和肝脏衰竭患者器官移植治疗的医疗技术公司，今天宣布已与 PAD Aviation 达成最终协议，计划进行投资，PAD Aviation 是一家总部位于德国的顶级私人航空运营商。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg"/></p>
<p>拟议的战略投资旨在支持 TransMedics 持续努力，通过在欧洲建立专门的器官移植空中和地面物流网络，复制成功的美国 NOP 和物流模式，以支持其 OCS™灌注平台和临床服务，目标是扩大对捐赠器官的获取并增加需要移植的患者在欧盟的移植数量。</p>
<p>&#34;在欧洲建立专门的移植空中物流网络是支持我们欧洲 NOP 战略的必要第一步，旨在将我们的 OCS 技术和综合物流模式的全部好处带给需要移植的欧洲患者。我们已经在意大利积极建立我们的存在，并计划逐步扩大对捐赠器官的获取并增加欧洲患者的移植数量。我们期待与 PAD 团队合作，在未来几年推进这一愿景，&#34;TransMedics 的总裁兼首席执行官 Waleed Hassanein 博士表示。</p>
<p>拟议的战略投资需满足双方在最终协议（&#34;协议&#34;）中规定的成交条件以及适用的监管条件。TransMedics 预计交易将在 2026 年晚些时候完成，但无法保证拟议交易将会完成。财务条款未予披露。</p>
<p><strong>关于 PAD Aviation service GmbH</strong> PAD Aviation 是一家领先的欧洲商务航空运营商，独立于商业航空公司。该公司在德国帕德博恩的 24/7 枢纽运营，提供最大灵活性，特别适用于器官运输等时间紧迫的任务。PAD Aviation 的飞机可以迅速到达欧洲各地的目的地。该公司运营现代化机队，包括九架 Embraer Phenom 300 飞机，并雇佣超过 40 名经过高度培训和类型认证的飞行员。PAD Aviation 持有有效的 EASA 航空运营证书（AOC）。</p>
<p><strong>关于 TransMedics Group, Inc.</strong> TransMedics 是全球便携式体外温灌注和捐赠器官评估的领导者。公司总部位于马萨诸塞州安多佛，成立的目的是解决器官移植中对更多和更好器官的未满足需求，并开发了技术以保持器官质量、在移植前评估器官的可行性，并可能增加捐赠器官在终末期心脏、肺和肝脏衰竭治疗中的利用率。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。这些前瞻性声明涉及各种事项，包括但不限于根据协议对 PAD Aviation 的拟议战略投资及其预期时间和完成情况；拟议战略投资的预期好处，包括建立专门的空中物流基础设施以支持欧盟的 OCS 和 NOP 平台；我们在欧洲复制美国 NOP 模式的战略，包括通过专门的空中和地面物流；航空许可、认证和运营基础设施在支持欧洲 NOP 中的预期作用；我们在意大利的持续商业运营；以及我们更广泛的国际扩展计划及相关成本。为此，所有非历史事实的声明均为前瞻性声明。&#34;相信&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;估计&#34;、&#34;继续&#34;、&#34;预期&#34;、&#34;打算&#34;、&#34;期望&#34;、&#34;应该&#34;、&#34;可以&#34;、&#34;目标&#34;、&#34;预测&#34;、&#34;寻求&#34;及类似表达旨在识别前瞻性声明。</p>
<p>这些前瞻性声明受到多种风险和不确定性的影响。管理层无法预测所有风险，也无法评估所有因素的影响或任何因素或因素组合可能导致的实际结果与我们可能做出的任何前瞻性声明中所包含或暗示的结果之间的重大差异。在这些风险和不确定性的背景下，本新闻稿中讨论的前瞻性事件和情况可能不会发生，实际结果可能与预期或前瞻性声明中暗示的结果存在重大和不利的差异。一些可能导致实际结果不同的关键因素包括：与对 PAD Aviation 的待定战略投资相关的风险和不确定性，包括可能导致协议终止的任何事件、变化或其他情况的发生；交易关闭条件未能及时或根本无法获得的风险；交易（或其公告或待定状态）对与关联方、客户、制造商、供应商、员工、其他商业伙伴或政府实体的关系的影响；交易成本；交易可能分散管理层对 TransMedics 持续业务运营的关注或以其他方式干扰 TransMedics 持续业务运营的风险；与将 PAD Aviation 与 TransMedics 整合相关的风险，包括保留关键员工的风险；经营航空业务的风险；进一步发展和增强国家 OCS 计划的能力相关的风险；以及在 TransMedics 向证券交易委员会（&#34;SEC&#34;）提交的文件中描述的其他因素，包括在 TransMedics 截至 2025 年 12 月 31 日的年度报告的&#34;风险因素&#34;标题下的内容，该报告于 2026 年 2 月 24 日提交给 SEC，以及我们后续向 SEC 提交的类似披露。本新闻稿中的前瞻性声明仅在本新闻稿日期时有效。可能导致我们实际结果不同的因素或事件可能会不时出现，我们无法预测所有这些因素。除非适用法律要求，否则我们不承担更新任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
<p><strong>投资者联系：</strong> Brian Johnston</p>
<p>Gilmartin Group</p>
<p>Investors@transmedics.com</p>
<p>来源：TransMedics Group, Inc.</p>

TMDX

<p>TransMedics Group, Inc. 宣布对总部位于德国的 PAD Aviation 进行战略投资，以建立一个专门的器官移植航空物流网络，覆盖整个欧洲。该计划旨在复制美国成功的模式，增强需要器官的患者对捐赠器官的获取。此项投资需满足成交条件和监管批准，预计将在 2026 年完成。TransMedics 专注于扩大在欧洲的业务，特别是在意大利，以增加移植数量并改善器官移植的质量</p>

<p><em>Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe</em></p>
<div class="lb-trans"><p><em>拟议对总部位于德国的 PAD Aviation 进行战略投资，这是一家顶级的欧洲私人航空运营商，旨在为 TransMedics 在欧洲建立专门的器官移植空中物流网络奠定基础</em></p>
</div><p>, /PRNewswire/ -- TransMedics Group, Inc. (&#34;TransMedics&#34;) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- TransMedics Group, Inc.（&#34;TransMedics&#34;）（纳斯达克：TMDX），一家正在改变终末期肺、心脏和肝脏衰竭患者器官移植治疗的医疗技术公司，今天宣布已与 PAD Aviation 达成最终协议，计划进行投资，PAD Aviation 是一家总部位于德国的顶级私人航空运营商。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg"/></p>
<p>The proposed strategic investment is intended to support TransMedics' ongoing efforts to replicate the successful U.S. NOP and logistics model by building a dedicated organ transplantation air and ground logistics network in Europe in support of its OCS™ perfusion platform and clinical services, with the goal of expanding access to donor organs and increasing transplant volumes for patients in need across the European Union.</p>
<div class="lb-trans"><p>拟议的战略投资旨在支持 TransMedics 持续努力，通过在欧洲建立专门的器官移植空中和地面物流网络，复制成功的美国 NOP 和物流模式，以支持其 OCS™灌注平台和临床服务，目标是扩大对捐赠器官的获取并增加需要移植的患者在欧盟的移植数量。</p>
</div><p>&#34;Building a dedicated transplant air logistics network in Europe is a necessary first step to supporting our European NOP strategy to bring the full benefits of our OCS technology and integrated logistics model to European patients in need of transplantation. We are already actively building our presence in Italy and our sights are set on expanding access to donor organs and increasing transplant volumes for patients across Europe over time. We look forward to working with the PAD team to advance this vision over the years ahead,&#34; said Waleed Hassanein, M.D., President and Chief Executive Officer of TransMedics.</p>
<div class="lb-trans"><p>&#34;在欧洲建立专门的移植空中物流网络是支持我们欧洲 NOP 战略的必要第一步，旨在将我们的 OCS 技术和综合物流模式的全部好处带给需要移植的欧洲患者。我们已经在意大利积极建立我们的存在，并计划逐步扩大对捐赠器官的获取并增加欧洲患者的移植数量。我们期待与 PAD 团队合作，在未来几年推进这一愿景，&#34;TransMedics 的总裁兼首席执行官 Waleed Hassanein 博士表示。</p>
</div><p>The proposed strategic investment is subject to the satisfaction of closing conditions specified in the definitive agreement between the parties (the &#34;Agreement&#34;) as well as applicable regulatory conditions. TransMedics expects the transaction to close later in 2026 but can provide no assurance that the proposed transaction will be consummated. Financial terms are not being disclosed.</p>
<div class="lb-trans"><p>拟议的战略投资需满足双方在最终协议（&#34;协议&#34;）中规定的成交条件以及适用的监管条件。TransMedics 预计交易将在 2026 年晚些时候完成，但无法保证拟议交易将会完成。财务条款未予披露。</p>
</div><p><strong>About PAD Aviation service GmbH</strong> PAD Aviation is a leading European business aviation operator, independent of commercial airlines. The company operates from its 24/7 hub in Paderborn, Germany, offering maximum flexibility—particularly for time-critical missions such as organ transport. From its centrally located base, PAD Aviation's aircraft can rapidly reach destinations across Europe. The company operates a modern fleet, including nine Embraer Phenom 300 aircraft, and employs more than 40 highly trained and type-rated pilots. PAD Aviation holds a valid EASA Air Operator Certificate (AOC).</p>
<div class="lb-trans"><p><strong>关于 PAD Aviation service GmbH</strong> PAD Aviation 是一家领先的欧洲商务航空运营商，独立于商业航空公司。该公司在德国帕德博恩的 24/7 枢纽运营，提供最大灵活性，特别适用于器官运输等时间紧迫的任务。PAD Aviation 的飞机可以迅速到达欧洲各地的目的地。该公司运营现代化机队，包括九架 Embraer Phenom 300 飞机，并雇佣超过 40 名经过高度培训和类型认证的飞行员。PAD Aviation 持有有效的 EASA 航空运营证书（AOC）。</p>
</div><p><strong>About TransMedics Group, Inc.</strong> TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.</p>
<div class="lb-trans"><p><strong>关于 TransMedics Group, Inc.</strong> TransMedics 是全球便携式体外温灌注和捐赠器官评估的领导者。公司总部位于马萨诸塞州安多佛，成立的目的是解决器官移植中对更多和更好器官的未满足需求，并开发了技术以保持器官质量、在移植前评估器官的可行性，并可能增加捐赠器官在终末期心脏、肺和肝脏衰竭治疗中的利用率。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, the proposed strategic investment in PAD Aviation pursuant to the Agreement and the expected timing and consummation thereof; the anticipated benefits of the proposed strategic investment, including the establishment of dedicated air logistics infrastructure to support the OCS and NOP platforms in the European Union; our strategy of replicating our U.S. NOP model in Europe, including through dedicated air and ground logistics; the expected role of the aviation licensing, certifications, and operational infrastructure in supporting the European NOP; our ongoing commercial operations in Italy; and our broader international expansion plans and the costs related thereto. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words &#34;believe,&#34; &#34;may,&#34; &#34;will,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;expect,&#34; &#34;should,&#34; &#34;could,&#34; &#34;target,&#34; &#34;predict,&#34; &#34;seek&#34; and similar expressions are intended to identify forward-looking statements.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。这些前瞻性声明涉及各种事项，包括但不限于根据协议对 PAD Aviation 的拟议战略投资及其预期时间和完成情况；拟议战略投资的预期好处，包括建立专门的空中物流基础设施以支持欧盟的 OCS 和 NOP 平台；我们在欧洲复制美国 NOP 模式的战略，包括通过专门的空中和地面物流；航空许可、认证和运营基础设施在支持欧洲 NOP 中的预期作用；我们在意大利的持续商业运营；以及我们更广泛的国际扩展计划及相关成本。为此，所有非历史事实的声明均为前瞻性声明。&#34;相信&#34;、&#34;可能&#34;、&#34;将&#34;、&#34;估计&#34;、&#34;继续&#34;、&#34;预期&#34;、&#34;打算&#34;、&#34;期望&#34;、&#34;应该&#34;、&#34;可以&#34;、&#34;目标&#34;、&#34;预测&#34;、&#34;寻求&#34;及类似表达旨在识别前瞻性声明。</p>
</div><p>These forward-looking statements are subject to a number of risks and uncertainties. Management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: risks and uncertainties related to the pending strategic investment in PAD Aviation, including the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement; the risk that conditions to closing of the transaction are not obtained in a timely manner or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees, other business partners or governmental entities; transaction costs; the risk that the transaction will divert management's attention from TransMedics' ongoing business operations or otherwise disrupts TransMedics' ongoing business operations; risks related to the ability to integrate PAD Aviation with TransMedics, including retaining key employees; risks related to operating an aviation business; risks related to the ability to further grow and enhance the National OCS Program; and other factors described in TransMedics' filings with the Securities and Exchange Commission (the &#34;SEC&#34;), including under the heading &#34;Risk Factors&#34; in TransMedics' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, and comparable disclosure in our subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.</p>
<div class="lb-trans"><p>这些前瞻性声明受到多种风险和不确定性的影响。管理层无法预测所有风险，也无法评估所有因素的影响或任何因素或因素组合可能导致的实际结果与我们可能做出的任何前瞻性声明中所包含或暗示的结果之间的重大差异。在这些风险和不确定性的背景下，本新闻稿中讨论的前瞻性事件和情况可能不会发生，实际结果可能与预期或前瞻性声明中暗示的结果存在重大和不利的差异。一些可能导致实际结果不同的关键因素包括：与对 PAD Aviation 的待定战略投资相关的风险和不确定性，包括可能导致协议终止的任何事件、变化或其他情况的发生；交易关闭条件未能及时或根本无法获得的风险；交易（或其公告或待定状态）对与关联方、客户、制造商、供应商、员工、其他商业伙伴或政府实体的关系的影响；交易成本；交易可能分散管理层对 TransMedics 持续业务运营的关注或以其他方式干扰 TransMedics 持续业务运营的风险；与将 PAD Aviation 与 TransMedics 整合相关的风险，包括保留关键员工的风险；经营航空业务的风险；进一步发展和增强国家 OCS 计划的能力相关的风险；以及在 TransMedics 向证券交易委员会（&#34;SEC&#34;）提交的文件中描述的其他因素，包括在 TransMedics 截至 2025 年 12 月 31 日的年度报告的&#34;风险因素&#34;标题下的内容，该报告于 2026 年 2 月 24 日提交给 SEC，以及我们后续向 SEC 提交的类似披露。本新闻稿中的前瞻性声明仅在本新闻稿日期时有效。可能导致我们实际结果不同的因素或事件可能会不时出现，我们无法预测所有这些因素。除非适用法律要求，否则我们不承担更新任何前瞻性声明的义务，无论是由于新信息、未来发展还是其他原因。</p>
</div><p><strong>Investor Contact:</strong> Brian Johnston</p>
<div class="lb-trans"><p><strong>投资者联系：</strong> Brian Johnston</p>
</div><p>Gilmartin Group</p>
<div class="lb-trans"><p>Gilmartin Group</p>
</div><p>Investors@transmedics.com</p>
<div class="lb-trans"><p>Investors@transmedics.com</p>
</div><p>SOURCE TransMedics Group, Inc.</p>
<div class="lb-trans"><p>来源：TransMedics Group, Inc.</p>
</div>

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH | TMDX Stock News

TransMedics 集团宣布计划通过战略投资 PAD 航空服务有限公司，创建首个专门的欧洲移植物流网络 | TMDX 股票新闻